Journal of Renal Injury Prevention最新文献_第5页

Evaluation of effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on estimated glomerular filtration rate, albuminuria and weight in diabetic kidney disease: A prospective cohort study 评价胰高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白-2抑制剂对糖尿病肾病肾小球滤过率、蛋白尿和体重的影响:一项前瞻性队列研究

Journal of Renal Injury Prevention Pub Date : 2023-06-20 DOI: 10.34172/jrip.2023.32062

Hayder Aledan, Sattar Jabar Saadi, Jawad Rasheed

{"title":"Evaluation of effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on estimated glomerular filtration rate, albuminuria and weight in diabetic kidney disease: A prospective cohort study","authors":"Hayder Aledan, Sattar Jabar Saadi, Jawad Rasheed","doi":"10.34172/jrip.2023.32062","DOIUrl":"https://doi.org/10.34172/jrip.2023.32062","url":null,"abstract":"Introduction: Albuminuria and baseline estimated glomerular filtration rate (eGFR) are the main predictors for progression of diabetic kidney disease (DKD). Objectives: The objectives of the study were to assess the effects of GLP1-RA (glucagon-like peptide-1 receptor agonists) and SGLT2i inhibitors therapy on estimated GFR, albuminuria, and weight in patients with DKD stage 3 and 4. Patients and Methods: This was a prospective cohort study of patients with stage 3 and 4 DKD over 6 months at Basra teaching hospital from November 1, 2020, to May 1, 2020. Baseline weight, UACR (urine albumin creatinine ratio), and eGFR were measured, and 6-months values were assessed between and within the group. Results: The baseline characteristics for the GLP-1 RA (GLP-1 receptor agonists) versus SGLT2i (sodium-glucose co-transporter-2 inhibitors) groups were mean ages 65 years versus 62.5 years, male (54.5% versus 50%), median weight (75 versus 80 kg), median eGFR (23.5 versus 39 ml/min/1.73 m2 ) and median UACR (925 mg/g versus 327 mg/g). In the GLP-1 RA group, after 6-months of therapy, there was 32% increase in eGFR (P<0.001), 29% decrease in UACR (P<0.001) and 4.5% decrease in weight while in the SGLT2i group, there was 4.5% decrease in eGFR (P=0.345), 34% decrease in UACR (P<0.001) and 2.8% decrease in weight (P=0.005). With cox-regression analysis, the HR for eGFR decline with SGLT2i therapy was 3.25 (95% CI: 1.1-9.97; P=0.039). Conclusion: GLP-1 RA, compared to SGLT2i therapy, caused an increase in eGFR in stages 3 and 4 CKD and caused more weight reduction but slightly less albuminuria reduction.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135236339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study of plasma neutrophil gelatinase-associated lipocalin as an early marker of acute kidney injury following contrast agents 血浆中性粒细胞明胶酶相关脂质运载蛋白作为造影剂后急性肾损伤早期标志物的研究

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-06-03 DOI: 10.34172/jrip.2023.32110

Samad Ghodrati, Seyedeh Masoomeh Mirrajei, N. Parsamanesh, K. Kamali, A. Esmaeilzadeh, A. Pezeshgi

{"title":"Study of plasma neutrophil gelatinase-associated lipocalin as an early marker of acute kidney injury following contrast agents","authors":"Samad Ghodrati, Seyedeh Masoomeh Mirrajei, N. Parsamanesh, K. Kamali, A. Esmaeilzadeh, A. Pezeshgi","doi":"10.34172/jrip.2023.32110","DOIUrl":"https://doi.org/10.34172/jrip.2023.32110","url":null,"abstract":"Introduction: Acute kidney injury (AKI) is a common illness among hospitalized patients, which increases mortality and morbidity rate. Creatinine and neutrophil gelatinase-associated lipocalin (NGAL) are the most commonly conducted biomarkers of AKI. Objectives: The aim of current study was to assess NGAL as an early biomarker for AKI diagnosis following contrast agents. Patients and Methods: To follow the aim of the present case-control research, 165 individuals were entered the study; 80 patients were selected from Valiasr hospital of Zanjan city, and 85 healthy individuals were enrolled voluntarily. There were not any significant differences in sex distribution among healthy subjects. Plasma NGAL and creatinine were measured immediately before and at 12 and 72 hours post-contrast agents’ exposure. Results: There were 89 males and 76 females in the study groups. The mean age was 61.3 ± 18.2 years and 62.1 ± 17.2 years in the intervention and healthy groups, respectively. The mean of serum creatinine and NGAL level were 1.0± 0.2 mg/dL and 63.6 ±23.6 ng/mL in the control and 0.92 ± 0.23 mg/dL and 110 ± 82.3 ng/mL in the case group, respectively. There were remarkable different between serum NGAL and creatinine in the both groups. The NGAL level in the healthy and the patient group were 63.6 ± 23.6 ng/mL and 100.1 ± 121.7 ng/mL, respectively, which was considerably different between the case and control groups (P=0.01). The highest level of specificity and sensitivity were 86 and 55.5; they could be the main appropriate options for defining cut off. Conclusion: The findings showed, that NGAL level is an extremely specific and sensitive indicator for AKI diagnosis after 72 hours. Hence, this approach can open a novel insight into the AKI therapies.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47858840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating intradialytic change of serum magnesium and its relation to intradialytic complications in chronic hemodialysis patients during one-month period 慢性血液透析患者一个月内血清镁的透析变化及其与透析并发症的关系

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-05-27 DOI: 10.34172/jrip.2023.9594

Shokouh Shayanpour, H. Shahbazian, Sanaz Asadi, K. Ahmadi Angali

引用次数: 0

Comparison of the efficacy of tadalafil in three different groups; patients on hemodialysis, first kidney transplant recipients, and second kidney transplant recipients 三组他达拉非疗效比较;血液透析患者，第一次肾移植受者和第二次肾移植受者

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-05-16 DOI: 10.34172/jrip.2023.31952

M. Dehghani, Amirhesam Alirezaei, A. Javid, N. Borumandnia, M. Aliasgari, Farshad Gholipour

{"title":"Comparison of the efficacy of tadalafil in three different groups; patients on hemodialysis, first kidney transplant recipients, and second kidney transplant recipients","authors":"M. Dehghani, Amirhesam Alirezaei, A. Javid, N. Borumandnia, M. Aliasgari, Farshad Gholipour","doi":"10.34172/jrip.2023.31952","DOIUrl":"https://doi.org/10.34172/jrip.2023.31952","url":null,"abstract":"Introduction: The efficacy of phosphodiesterase-5 inhibitors (PDE5Is) on the improvement of erectile dysfunction (ED) in second kidney transplant (KT) recipients has not been studied before. Objectives: We aimed to compare the efficacy of tadalafil in three groups: hemodialysis (HD) patients, first KT recipients (KT1) and second KT recipients (KT2) with bilaterally ligated internal iliac arteries (IIAs). Patients and Methods: Age-matched men with ED were included in the study. Patients divided into three groups; HD, KT1 and KT2. The international index of erectile function 15 (IIEF-15) questionnaire was used to assess the baseline erectile function. Tadalafil was administered in a dose-escalation method for three months. Patients were reevaluated by the questionnaire at three months. The mean score evolution was compared between the study groups by Kruskal-Wallis H test. Results: Total number of 106 patients in three groups was included in the final analysis. There was no significant difference between the study groups in terms of age, body mass index (BMI), blood pressure and frequency of smoking, opium, or alcohol use. Tadalafil was safe and effective in all three groups. The mean IIEF score evolution in HD, KT1 and KT2 groups was 16.4 (58.7% increase from baseline), 19.3 (45.0% increase) and 20.4 (52.7% increase), respectively. Conclusion: Tadalafil is effective and safe in the management of ED even after the second kidney transplantation when the IIAs are cut bilaterally. The response rate is similar to first KT recipients and HD patients. Trial Registration: The trial protocol was approved by the Thai Clinical Trials Registry (https://www.thaiclinicaltrials.org/show/TCTR20220310008, ethical code# IR.SBMU. UNRC.1396.43).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46244242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis 他汀类药物与肾细胞癌的关系；系统综述与meta分析

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-04-27 DOI: 10.34172/jrip.2023.32192

P. Ramezannezhad, Mohammadreza Khosravifarsani

{"title":"The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis","authors":"P. Ramezannezhad, Mohammadreza Khosravifarsani","doi":"10.34172/jrip.2023.32192","DOIUrl":"https://doi.org/10.34172/jrip.2023.32192","url":null,"abstract":"Introduction: Renal cell carcinoma (RCC) is the most prevalent renal cancer in adults, with a rising global incidence. There has long been an ambiguity about the effect of statin administration on the incidence of RCC. The present meta-analysis aims to evaluate the relationship between statin usage and RCC. Materials and Methods: Cochrane, Web of Science, Scopus, and PubMed databases, as well as the Google Scholar search engine, were queried for relevant articles. The data were statistically analyzed by STATA 14 software. The significance level of the tests was considered P<0.05. Results: In 15 reviewed articles, 46 735 subjects used statin, and 673 752 did not. The odds ratio (OR) between statin usage and the risk incidence of RCC was 0.86 (OR: 0.86; 95% CI: 0.63, 1.17) overall and estimated as 0.94 (OR: 0.94; 95% CI: 0.69, 1.28) in males and 0.92 (OR: 0.92; 95% CI: 0.66, 1.28) in females. The odds ratio of statin administration and the incidence risk of RCC was 0.74 (OR: 0.74; 95% CI: 0.37, 1.49) in case-control and 0.96 (OR: 0.96; 95% CI: 0.79, 1.17) in cohort studies. In addition, the impact of statin usage on overall survival (OS) in RCC was 0.65 (HR: 0.65; 95% CI: 0.53, 0.80), and this relationship was statistically significant. However, the effect of statin usage was 0.68 (HR: 0.68; 95% CI: 0.45, 1.02) on progression-free survival (PFS) and 1.24 (OR: 1.24; 95% CI: 0.66, 2.32) on disease progression (DP), and these relationships were statistically non-significant. Conclusion: The OS of RCC patients was 35% higher in statin users than in non-users. However, no relationship between statin usage and the incidence risk of RCC was found. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (CRD42023393647).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42684236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is furosemide a nephrotoxic for hospitalized patients? 速尿对住院患者有肾毒性吗?

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-04-10 DOI: 10.34172/jrip.2023.32164

Kyaw Kyaw Hoe, Swane Rowe-Gardener, Thant Hnin Saint Hoe

{"title":"Is furosemide a nephrotoxic for hospitalized patients?","authors":"Kyaw Kyaw Hoe, Swane Rowe-Gardener, Thant Hnin Saint Hoe","doi":"10.34172/jrip.2023.32164","DOIUrl":"https://doi.org/10.34172/jrip.2023.32164","url":null,"abstract":"Introduction: Acute kidney disease (AKI) is preventable in certain situations. Long-term and/or high dose furosemide may lead to acute kidney injury. Objectives: We aimed to find the risk of AKI among hospitalised patients who were exposed to furosemide. Patients and Methods: This is a retrospective cohort study of hospitalised patients who received furosemide therapy during the admission between 2019 and 2021. Exposure to furosemide was grouped into low dose (≤ 40 mg/d) or high dose (>40 mg/d) and short-term use (≤ 72 hours) or long-term use (>72 hours). Risk of acute kidney injury was calculated as odds ratios with a 95% confidence interval (CI). A P value <0.05 was considered statistically significant. Results: Of 314 patients who received furosemide intravenously or orally, 197 patients (62.7%) had acute kidney injury. Of 197 patients with acute kidney injury, 110 patients (55.9%) received the dosage of >40 mg/d and 121 patients (61.4%) were on furosemide for >7 days (odds ratios [ORs]: 5.46, 95% CI: 3.17 to 9.39, P≤0.001 and ORs: 7.72, 95% CI: 4.4 to 13.52, P≤0.001). In comparison, the 87 (44.1%) patients who received ≤40 mg/d of furosemide had a lower incidence of AKI (ORs: 0.25, 95% CI: 0.13 to 0.48, P≤0.001) and only 21 of the patients (10.6%) who received furosemide for < 7 days were found to have acute kidney injury (ORs: 0.08, 95% CI: 0.04 to 0.14, P≤0.001). The combined effect of high dose and long-term furosemide therapy is more consequential as we found that 100 (31.8%) patients who received furosemide >40 mg for >72 hours, 96 patients (30.6%) developed AKI (ORs: 26.8, 95% CI: 9.53 to 75.63, P≤0.001). Conclusion: Among hospitalised patients, exposure to high dose furosemide or prolonged use of furosemide is associated with AKI. The risk is more when high dose furosemide is administered for longer than 72 hours. Presence of underlying diabetes, hypertension, cardiac failure and chronic kidney disease, are also associated with furosemide -induced hospital-acquired acute kidney injury.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49143043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare case of urosepsis caused by multidrug-resistant Escherichia hermannii in an immunocompetent toddler 一例罕见的尿脓毒症引起多药耐药赫氏埃希菌在一个免疫能力的幼儿

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-02-25 DOI: 10.34172/jrip.2023.32077

Roham Sarmadian, P. Yousefichaijan, M. Kahbazi

引用次数: 0

Evaluation of hemodialysis adequacy using urea reduction rate and related factors in Iranian patients’ undergoing hemodialysis in Guilan, Iran 伊朗桂兰地区血液透析患者尿素还原率及相关因素评价血液透析充分性

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-02-18 DOI: 10.34172/jrip.2023.32132

M. Yaseri, H. S. Fayazi, Seyyedeh Sahereh Mortazavi Khatibani, Azin Hajipoor

{"title":"Evaluation of hemodialysis adequacy using urea reduction rate and related factors in Iranian patients’ undergoing hemodialysis in Guilan, Iran","authors":"M. Yaseri, H. S. Fayazi, Seyyedeh Sahereh Mortazavi Khatibani, Azin Hajipoor","doi":"10.34172/jrip.2023.32132","DOIUrl":"https://doi.org/10.34172/jrip.2023.32132","url":null,"abstract":"Introduction: Dialysis quality is an important factor in reducing inability and mortality in chronic kidney failure patients and can enhance their life quality and social activity. Objectives: The aim of this investigation was to examine the efficacy of dialysis based on urea reduction rate (URR) and the associated factors in hemodialysis patients due to the lack of clarity on the adequacy of dialysis. Patients and Methods: This multicenter cross-sectional study was conducted on 344 hemodialysis patients over 18 years and referred to seven dialysis centers in Guilan, Iran. The adequacy of dialysis was obtained using URR (>65%) criteria. Results: The mean URR of studied patients was 63 ±10.4%. The desirable dialysis adequacy was reached in 45.9% of the patients. There was a significant negative association between URR and BMI (r= -0.155, P =0.005). Patients who had normal calcium levels had significantly higher URR adequacy than patients with abnormal calcium levels ( P <0.001). The URR criterion was contrariwise associated to blood pressure before and after dialysis ( P <0.05). There was a significant association between the length of the time, patients underwent dialysis (in year) and URR (R=125, P =0.023). Conclusion: This study indicated that URR is a desirable criterion for dialysis adequacy, which was associated with blood pressure, serum calcium level and body mass index (BMI). These findings suggest providing treatment strategies based on these findings to enhance the effect of dialysis adequacy.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46402186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis 二甲双胍给药对肾癌患者癌症特异性生存、总生存、无进展生存和疾病进展的影响系统回顾和荟萃分析

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-02-09 DOI: 10.34172/jrip.2023.32158

H. Nourmohammadi, Tayebe Jamshidbeigi, Zahra Abdan, Diana Sarokhani, M. Fakhri, Shakiba Alaienezhad

{"title":"The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis","authors":"H. Nourmohammadi, Tayebe Jamshidbeigi, Zahra Abdan, Diana Sarokhani, M. Fakhri, Shakiba Alaienezhad","doi":"10.34172/jrip.2023.32158","DOIUrl":"https://doi.org/10.34172/jrip.2023.32158","url":null,"abstract":"Introduction: The increase in the incidence of renal cell carcinoma (RCC) has been reported worldwide. The anti-cancer impacts of metformin on the various types of cancer have been observed in clinical studies. Therefore, this study aims to survey the effect of metformin use on RCC patients using systematic review and meta-analysis methods. Materials and Methods: In this research, Cochrane, Web of Science, PubMed, Scopus databases, and Google Scholar web browser were searched using standard keywords. Data were analyzed with STATA 14 software. The significance level of tests P<0.05 was considered. Results: The improvement in the progression-free survival (PFS) (HR: 0.72 (95% CI: 0.54, 0.94), P=0.169, I2=37.8%) and cancer-specific survival (CSS) (HR: 0.36 (95% CI: 0.18, 0.75), P=0.339, I2=7.5%) was observed in eight studies with 10404 patients affected by RCC. However, no significant statistical effect was observed on the improvement in the disease progression (OR: 1.10 (95% CI: 0.85, 1.42), P=0.326, I2=0%) and cancer overall survival (OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%). Conclusion: This study showed metformin administration improved CSS and PFS in RCC patients. More studies are warranted on the effect of metformin on the improvement in disease progression and OS of cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID= CRD42022369108; https://www.crd.york. ac.uk/prospero/display_record.php?ID=CRD42022369108).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41348665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review and meta-analysis of prevalence of urinary tract infection in childhood 儿童尿路感染患病率的系统评价和荟萃分析

IF 0.7

Journal of Renal Injury Prevention Pub Date : 2023-02-09 DOI: 10.34172/jrip.2023.32160

Tayebe Jamshidbeigi, A. Adibi, Seyed Mohammad Amin Hashemipour, Diana Sarokhani, A. Hasanpour Dehkordi, M. Fakhri, Shakiba Alaienezhad

{"title":"A systematic review and meta-analysis of prevalence of urinary tract infection in childhood","authors":"Tayebe Jamshidbeigi, A. Adibi, Seyed Mohammad Amin Hashemipour, Diana Sarokhani, A. Hasanpour Dehkordi, M. Fakhri, Shakiba Alaienezhad","doi":"10.34172/jrip.2023.32160","DOIUrl":"https://doi.org/10.34172/jrip.2023.32160","url":null,"abstract":"Introduction: Urinary tract infection (UTI) is considered as one of the most important causes of fever and hospitalization in children. The present study was conducted with the aim of investigating the prevalence of UTIs in children through meta-analysis. Methods: This meta-analysis study was conducted on individuals aged >18 years. In order to retrieve the studied, the following domestic and foreign databases were searched: PubMed, Scopus, Web of Science, and Cochrane. The obtained data were analyzed in STATA version 14 at the significance level of P<0.05. Results: In 36 studies with 78212 samples published between 2000 and 2021, the prevalence of UTIs in children was reported at 15% (95% CI: 13%, 17%). It was 16% in girls (95% CI: 12%, 19%) and 10% in boys (95% CI: 7%, 13%). The most common cause of UTI in children was Escherichia coli with 58% (95% CI: 46%, 69%). The least common prevalence was reported in the UK with 6% (95% CI: 5%, 6%) and the USA with 6% (95% CI: 5%, 8%) and the highest prevalence was reported in Iraq with 43% (95% CI 39%, 48%). Conclusion: Approximately one out of 10 people suffers UTI and this rate is increasing over time and the prevalence of UTIs in girls is about 1.5 times higher than that in boys. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42021290886, https://www.crd.york.ac.uk/ prospero/display_record.php?ID=CRD42021290886).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42005619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3